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Abstract 
Background: Candida blood stream infection (BSI) is an important cause of sepsis and sepsis-related mortality. 
Common risk factors for Candida BSI include very low birth weight, central vascular catheterization (CVC), use of 
broad-spectrum antibiotics, endotracheal intubation, and prolonged hospital stay.  Although C. albicans accounts for 
Candida BSI among infants, but recent studies have detected a shift towards non-albicans Candida (NAC) species. 
Aims & Objectives: To isolate and identify different species of candida from blood samples. To find out the 
antifungal sensitivity pattern of the fungus isolated. To identify various risk factors associated with Candidemia in 
patient admitted in critical care unit.Methods: BACT/ALERT 3D Paediatric bottle was used for fungal blood 
culture.  Inoculation on Blood agar and Sabourads dextrose agar (SDA) was made from the culture positive bottles. 
After the growth obtained from SDA, Gram staining, Germ tube test, CHROM agar Candida Medium and Sugar 
fermentation and biochemical Test kits (KB006 Hi Candida Identification Kit) were used for identification of 
various Candida Spp. Anti fungal susceptibility test was carried out by Kirby-Bauer disc diffusion   method.  
Results: Out of 84 different species of Candida, C. albicans were the highest number (32.14%), followed by 
23.81% of C. tropicalis, 21.42% C. parapsilosis. Susceptibility for voriconazole, fluconazole and amphotericin B 
was 85.71%, 75% and 64.28%, respectively. NAC (57 isolates) were more resistant to azole group of antifungal, 
especially commonly used antifungal like fluconazole (45.6%). Conclusion: Candidemia is a significant problem in 
Pediatrics age group patients, especially in NICU and SNCU. A gradual but significant epidemiological shift to 
higher isolation of NCA is being noticed. 
Keywords: Paediatric, C. albicans, Non-albicans Candida (NAC), Blood stream infection (BSI), Anti-fungal 
susceptibility test, Resistance, Azole group 
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Introduction
Candidemia (presence of yeasts like fungus in blood) is 
caused by Candida species. Candida blood stream 
infection (BSI) is an important cause of sepsis and 
sepsis- related mortality[1]. Common risk factors for 
Candida BSI include prematurity and very low birth 
weight (VLBW), central vascular catheterization, 
parenteral nutrition, use of broad-spectrum antibiotics, 
H2 blockers and corticosteroids, endotracheal 
intubation,  and prolonged hospital stay[1,2]. Although 
C. albicans accounts for 45–55% of Candida BSI 
among infants[1,2,3]. Recent studies have detected a 
shift towards non- albicans Candida (NAC) species , 
which are often associated with high mortality and 
poor antifungal susceptibility [4,5,6,7]. Among these 
species, C. albicans is still the most common pathogen 
in spite of its dwindling share. The isolation rates of 
NCA, other than C. albicans vary according to the 
features (age, underlying diseases, hospitalization 
ward, etc) of patient population. To illustrate, C. 
Parapsilosis causes 30% of the candidemia cases 
among newborns[8].Although there are over 
150 Candida species in nature, only 15 of them are 
human pathogens. In the last 20 years, a change has 
been observed in the rates of Candida species isolated 
from patients with candidiasis. The incidence of C. 
albicans has decreased, while that of the non-albicans 
Candida has increased. Although this change has 
multiple causes, the foremost of these are fluconazole 
use and the increasing popularity of venous 
catheters[8,9].The scope of candidiasis covers a wide 
range of diseases from more superficial and milder 
clinical manifestations such as esophageal or 
oropharyngeal candidiasis to serious infections 
including blood stream infections (BSIs) and 
disseminated candidiasis. Currently, there are more 
than 150 known species of Candida that have been 
identified  . Although the isolation frequencies may 
vary, in the last 20–30 years, it has been determined 
that in 95% of infections, the pathogens involved are C. 
albicans, C. glabrata, C. parapsilosis, C. tropicalis, 
and C. krusei[8].   According to the data provided by 
the Centers for Diseases Control and Prevention (CDC) 
and the National Healthcare Safety Network, 
 Candida species are ranked fifth among hospital-
acquired pathogens and fourth among BSI 
pathogens[8-11].According to the results of the 
SENTRY Antimicrobial Surveillance Program, 1,354 
infection episodes related to Candida species were 
detected between 2008 and 2009 and 36.5% of these 
were community-acquired. Community-acquired 
candidemia was found to be significantly higher in 
North America (63.5%) than in Europe (22.4%)[12]. 
The present study was undertaken to assess the species 
distribution, susceptibility pattern, risk factors and 
outcome of neonates developing Candida BSI during 
hospital stay. 
 
Materials  and Methods 
This was a prospective study which was conducted at 
the Department of Microbiology and Paediatrics at 
Burdwan Medical College and Hospital over a 2 years 
of tenure (January 2018 to December 2019). 
Permission of the Institutional Ethics Committee was 
obtained before commencement of the study. A total 
801 blood samples of clinically diagnosed sepsis 
patients’ was collected in BACT/ALERT 3D SYSTEM 
Paediatrics bottles, from Sick neonatal care unit 
(SNCU), Paediatric ICU (PICU) and in Neonatal ICU 
(NICU) are included.Samples from the culture positive 
bottles were inoculated on blood agar and Sabouraud’s 
dextrose agar (SDA) and incubated at 37⁰C for 24-48 
hours. After the growth obtained from SDA and blood 
agar media, gram stain were carried out to identify the 
buddying cyst. Germ tube test was carried out to 
differentiate Candida albicans and NCA. 
Chlamydospore formation was carried out to diagnose 
different species of Candida. Chlamydospores are 
highly refractive, thick walled cells that are produced 
under nutrient poor, oxygen limited condition and in 
low temperature[1,10,18] CHROM agar Candida 
Medium was  used for presumptive identification of 
various Candida Spp. This is based on the direct 
detection of specific enzymatic activities by adding 
certain substrates of fluorochromes to the media. A 
subculture will be made from primary isolation media 
in CHROM agar Candida Medium, and it will be 
incubated at 30ºC for 24-48 hours. After 24 -48 hours, 
colony morphology and colour of the colony will be 
noted. CHROM agar Candida was used to differentiate 
several Candida Spp by colour and morphology. Sugar 
fermentation and biochemical Test kits (KB006 
HiCandida Identification Kit) was carried out. The 
yeast to be identified was isolated on SDCA.The 
inoculum was prepared by picking 2-4 well isolated 
colonies and making homogeneous suspension in 2-3 
ml sterile saline Each well of the kit was inoculated 
with 50µl of the above inoculum by surface inoculation 
or  by stabbing each individual well with a loop full of 
inoculum. Incubated at 22.5ºC ±2.5ºC for 24-48 hours. 
 
Anti Fungal Susceptibility Test (AFST) 
This was   carried out next by the disc diffusion. Using 
amphotericin-B (100 unit), voriconazole (1µg) and 
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fluconazole (10ug). Mueller Hinton agar supplemented 
with 2% glucose and methylene blue dye 0.5µg/ml. 
The risk factors for candidemia will be identified from 
the demographic data of the patients or from hospital 
records for the retrospective arm. Presence of the 
following factors were considered as risk factors and 
were matched for association with positive candida 
culture: 
 
Risk factors for invasive candidiasis for children 
• Mechanical ventilation 
• Usage of antibiotics with broad spectrum 
• Catheter in situ e.g. central line, urinary catheter, 
central venous catheter  
• Prolonged stay in hospital>14 days  
 
 
Results 
Out of 801 blood samples, 47.31% were culture 
positive. Among which 56.67% were Gram positive 
cocci, 22.95% were Gram negative bacilli and 21.37% 
(n=84) were Candida isolates. Nearly 64. 28% isolates 
of Candida were obtained from NICU, followed by 
29.76% were from SNCU, 5.95% were PICU. ICU 
male patients had outnumbered the females. About 
46.42% patients were diagnosed with sepsis with PUO, 
followed by 21.42% suffering from pneumonia, 
14.28% were diagnosed with congenital heart disease. 
C. albicans were the highest numbers of isolate, 
accounting for 32.14%, next to it was C. tropicalis 
(23.81%), C. parspsilosis (21.42%), C. krusei (14.28%) 
and C.glabrata(8.33%).Voriconazole  revealed 85.71% 
sensitivity, followed by fluconazole  and amphotericin 
b accounting for 75 % and 64.28% sensitivity rate 
respectively.  
Table 1: Direct detection of different species of Candida on the basis of different colour on Chrome agar 
media 
Candida spp Colour on CHROM agar media 
C.albicans Light green 
C.glabrata Grey to  white 
C.tropicalis Steel blue 
C.parapsilosis Off white to cream 
C.krusei Purple, fuzzy 
 
 
Figure1: Distribution of different culture positive isolates 
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Figure 2: Chrome agar Candida medium 
 
Figure 3: Sugar fermentation and biochemical Test kits (KB006 HiCandida Identification Kit) 
Table 2: Interpretation of Sugar fermentation and biochemical Tests by different species of candida by 
KB006 HiCandida Identification Kit 
Candida spp Urease  Meli
bios
e  
Lact
ose  
Maltose  Sucro
se  
Gal
ac 
tose  
Cell
pb 
iose  
Inosit
ol  
Xylo
se  
Dulcit
ol  
Raffinose  Treha
lose  
C.albicans - - - + - + + - - + - + 
C.glabrata + - - - - - - - - - - - 
C.tropicalis - - - - - - + - - - - - 
C.parapsilo
sis 
- - - + + + + - - + + + 
C.krusei + _- - - - - - - - - - - 
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Fig 4: Distribution of different species of Candida 
Table 3: Distribution of different species of Candida according to the risk factors 
Sources of infection (Potential risk factors) Candida albicans NCA (n=57) 
Mechanical ventilation 51.8% 54.4% 
Catheter in –situ 51.8% 54.4% 
Usages of antibiotics with broad spectrum 37% 66.66% 
Prolonged stay in hospital  <14 days 81% 82.4% 
 
 
Figure 5: Antifungal susceptibility test (AFST) 
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Figure 6: Antifungal susceptibility testing (AFST) 
Discussion 
Candida BSI  is an emerging and life threatening 
conditions that endangers the critically ill patients 
admittedat ICU  .In the present study the incidence of 
Candida BSI was 10.48% of total clinically suspected 
patients’ of sepsis. C. albicans  was the most 
commonly isolated Candida species, followed by C. 
tropicalis and C. parapsilosis. All total the isolates of 
NCA was outnumbered the total isolated of C.albicans 
(Fig. 4) .this finding was consistent with the results of  
a study that reported a predominance of non- C. 
albicans species (64%  non-C. albicans versus 36% 
C.albicans)[13] Several studies also reported this 
pattern in contrast to the results ofolder 
published[14,15].Since the last fewdecades,  the 
epidemiology of Candidemia has been evolving as 
there is a progressive shift from a predominance 
of Candida albicans toward a predominance of non-
albicans Candida spp, especially C. glabrata, C. 
parapsilosis, and C. tropicalis. Emergence of NAC 
species and their association with higher mortality and 
longer duration of hospital stay is a cause for 
concern[16].   This scenario was  quite similar  with our 
present study as, we have observed that  a higher 
incidence of candidemia is associated with prolonged 
hospital stay: more than 14 days (Table 3)The 
incidence of sepsis  and duration of hospital stay were 
significantly higher in NAC BSI. Catheter in situ and 
and hospital stay >14 days were independent predictors 
of  NAC BSI, in this study. Unlikely, another study by 
Khairat et al revealed that the most important risk 
factor was previous exposure to antibiotics for >14 
days[13]. 
 
The colonization of candida on the skin and on the 
mucosal membrane is one of the pivotal factors for 
commencing Candidemia. After the colonization on the 
skin and mucus membrane, Candida disrupt the host's 
natural epithelial barrier, due to insertion of 
intravascular catheters or mechanical ventilators or 
surgery or burns. Candidemia can occur in a hospital 
setting as a primary Central Line Associated 
Bloodstream Infection (CLABS I) or secondary 
bloodstream infection[16]. In our study we have 
founded that 51.8% of  C. albicans  isolates  and 54.4% 
of NAC were obtained from those patients in whom 
catheters were in situ (Table 3). It is evident that the 
BSI due to candida species contributes to mortality is 
substantial and the targeted and appropriate antifungal 
therapy can control this menace. In this present study, 
candidemia was most frequently identified in NICU 
(64%) and 29.8% were from SNCU. These findings 
were consistent with another study where 59% were in 
ICU and in neonates 35%[13]. These statistics depicted 
that the growing number of isolates of Candida 
creating a problem in ICUs. In the last few decades, 
antifungal susceptibility testing has become 
standardized and nowadays has the same role of the 
antibacterial susceptibility testing in microbiology 
laboratories. With regards to antifungal susceptibility, 
64.28%of isolates were sensitive to Amphotericin B 
(Fig 6). However, some other studies reported lower 
incidence of resistance, unlike this study. A study by 
Khairat et al revealed only 35% isolates were 
resistance to Amphotericin-B[13]. Similarly a study by 
Sook-In Jung, et al reported lower incidence of 
Amphotericin–B resistance[14]. Back to 2005 to 2012,  
some previous studies even reported  no resistance to 
Amphotericin-B at all[15-17]. This increasing trends of 
0.00%
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Amphotericin–B  resistance might be due to extensive 
use of Amphotericin B or unjudicial use of broad 
spectrum use of antibiotics or long time presence of  
catheter–in-situ[13]. The rate of Fluconazole sensitive 
rate was 75%. However, Voriconazole revealed 85.7% 
sensitivity rate. Both of these findings of our study 
were consistence with the result ofanother 
study[13].According to some other study the rate of 
resistance to fluconazole and variconazole is pretty 
much lower[14].Many studies on the correlation of in 
vitro results with the outcome of patients have been 
performed, reaching the conclusion that infections 
caused by resistant strains have worse outcome than 
those caused by susceptible Candida isolates. These 
studies have allowed the development of interpretative 
breakpoints for Candida spp, the most frequent agents 
of fungal infections in the world. In summary, 
antifungal susceptibility tests have become essential 
tools to guide the treatment of fungal diseases, to know 
the local and global disease epidemiology, and to 
identify resistance to antifungals.Prevention of risk 
factors in susceptible paediatrics age group with early 
removal of central line or urinary catheter, early 
reporting of fungal culture till species level of Candida  
and susceptibility testing are necessary for appropriate 
institution of treatment and better outcome. Frequent 
empirical use of fluconazole and amphotericin B may 
be avoided as it may lead to a shift in species 
distribution and higher antifungal resistance.  
Conclusion  
Candidemia is a significant problem in Pediatrics age 
group patients, especially in NICU and SNCU. A 
gradual but significant epidemiological shift to higher 
isolation of NCA is being noticed. It is imperative that 
routine screening of Candida isolates to the species 
level is essential and could assist clinicians in 
promoting adoption of important prophylactic and 
treatment guidelines for its improved management. 
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